FFA
MDGL icon

Farther Finance Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Farther Finance Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$434K Buy
862
+756
+713% +$400K ﹤0.01% 1701
2026
Q2 		$56.8K Sell
106
-3
-3% -$1.54K ﹤0.01% 3146
2026
Q1 		$57.8K Sell
109
-31
-22% -$14.8K ﹤0.01% 2892
2025
Q4 		$81.5K Buy
140
+36
+35% +$18.4K ﹤0.01% 2475
2025
Q3 		$47.7K Buy
104
+13
+14% +$4.85K ﹤0.01% 2464
2025
Q2 		$27.5K Sell
91
-20
-18% -$5.96K ﹤0.01% 2475
2025
Q1 		$36K Buy
111
+99
+825% +$32.5K ﹤0.01% 2073
2024
Q4 		$3.7K Buy
12
+4
+50% +$1.13K ﹤0.01% 2787
2024
Q3 		$1.7K Sell
8
-3
-27% -$767 ﹤0.01% 3049
2024
Q2 		$3.07K Buy
+11
New +$2.62K ﹤0.01% 2615

Other funds holding MDGL

CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
CI
CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return

Farther Finance Advisors's MDGL Position: Q3 2026 in Review

Farther Finance Advisors increased its Madrigal Pharmaceuticals (MDGL) stake by 713% in Q3 2026, buying an estimated $400K and bringing the position to 862 shares worth $434K. The position accounts for ﹤0.01% of the portfolio, ranked #1701.

Farther Finance Advisors first reported a position in MDGL in Q2 2024 and has held it in 10 quarters since. 8 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.

  • Farther Finance Advisors held 862 shares of Madrigal Pharmaceuticals worth $434K as of Q3 2026.
  • Farther Finance Advisors bought 756 Madrigal Pharmaceuticals shares in Q3 2026, an estimated $400K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #1701 holding.
  • Farther Finance Advisors first reported a position in Madrigal Pharmaceuticals in Q2 2024 and has held it in 10 quarters since.
  • 8 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.